SEATTLE--(BUSINESS WIRE)-- NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, today announced the launch of the nCounter® ...
Targeted therapies for cancer are increasingly being developed as an alternative for, and in addition to, immunotherapy. Altered tumor signaling can be exploited to single-out cancer cells for ...
SEATTLE--(BUSINESS WIRE)--NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for translational research and molecular diagnostic products, today announced the ...
Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor DNA assay. Safety and activity of DCR-MYC, a first-in-class Dicer-substrate small interfering ...
10x Genomics has begun commercial shipments of a new 5,000–plex gene expression panel that increases plex by an order of magnitude over previous panels, a month after announcing the launch of the ...
Exposing the criminal record of every blood sample: Use of SOMAmer technology and sample mapping vectors to mitigate false biomarker discoveries in lung cancer. This is an ASCO Meeting Abstract from ...
Commercially available gene expression tests for predicting prostate cancer progression appear to be less accurate in black vs white men, according to a new study. Commercial gene expression tests ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results